These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17541852)

  • 1. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.
    Zourková A; Cesková E; Hadasová E; Ravcuková B
    J Sex Marital Ther; 2007; 33(4):343-55. PubMed ID: 17541852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment.
    Zourková A; Hadasová E
    J Sex Marital Ther; 2002; 28(5):451-61. PubMed ID: 12378847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire.
    Clayton AH; Owens JE; McGarvey EL
    Psychopharmacol Bull; 1995; 31(2):397-413. PubMed ID: 7491398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.
    Pae CU; Masand PS; Marks DM; Krulewicz S; Han C; Peindl K; Mannelli P; Patkar AA
    World J Biol Psychiatry; 2009; 10(4 Pt 2):435-41. PubMed ID: 19382010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of mania in depression by paroxetine.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of clomipramine on CYP2D6 activity].
    Szewczuk-Bogusławska M; Kiejna A; Grzesiak M; Beszłej JA; Chlebowska I; Orzechowska-Juzwenko K; Milejski P
    Psychiatr Pol; 2007; 41(2):243-9. PubMed ID: 17598433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
    Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
    Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions.
    Atmaca M; Kuloglu M; Tezcan E
    Int J Impot Res; 2005; 17(2):201-3. PubMed ID: 15284834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxepin inhibits CYP2D6 activity in vivo.
    Szewczuk-Bogusławska M; Kiejna A; Beszłej JA; Orzechowska-Juzwenko K; Milejski P
    Pol J Pharmacol; 2004; 56(4):491-4. PubMed ID: 15520506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
    Preskorn SH
    J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDR1 in paroxetine-induced sexual dysfunction.
    Zourková A; Slanař O; Jarkovský J; Palčíková I; Pindurová E; Cvanová M
    J Sex Marital Ther; 2013; 39(1):71-8. PubMed ID: 23152970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.
    Wu KY; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):109-14. PubMed ID: 18289149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.